We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
-1.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
-$253M
(-18%)
Cap. Flow
-$97.3M
Cap. Flow
% of AUM
-8.43%
Top 10 Holdings %
Top 10 Hldgs %
65.98%
Holding
89
New
12
Increased
29
Reduced
25
Closed
19
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
1.2
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$63.1M |
| 2 |
Natera
NTRA
|
+$45.2M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$26.6M |
| 4 |
Illumina
ILMN
|
+$14.6M |
| 5 |
Seres Therapeutics
MCRB
|
+$9.91M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$67.4M |
| 2 |
Avantor
AVTR
|
+$28M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$21.6M |
| 4 |
argenx
ARGX
|
+$16.9M |
| 5 |
Fate Therapeutics
FATE
|
+$16.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.39% |
| 2 | Miscellaneous | 27.61% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
CALL
Celldex Therapeutics
CLDX
$2.17B
| – | – |
-191,600
| Closed | -$5.17M | – |
|
|
77
PUT
Celldex Therapeutics
CLDX
$2.17B
| – | – |
-60,600
| Closed | -$1.63M | – |
|
78
DexCom
DXCM
$32.4B
| – | – |
-14,468
| Closed | -$1.08M | – |
|
79
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-478,245
| Closed | -$5.14M | – |
|
80
HealthEquity
HQY
$7.61B
| – | – |
-127,043
| Closed | -$7.8M | – |
|
81
PUT
iShares Russell 2000 ETF
IWM
$76.1B
| – | – |
-50,000
| Closed | -$8.47M | – |
|
82
DELISTED
Masimo
MASI
| – | – |
-5,984
| Closed | -$782K | – |
|
83
Qiagen
QGEN
$9.5B
| – | – |
-179,093
| Closed | -$8.96M | – |
|
84
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
| – | – |
-465,000
| Closed | -$175M | – |
|
85
Tandem Diabetes Care
TNDM
$1.13B
| – | – |
-256,268
| Closed | -$15.2M | – |
|
86
Zentalis Pharmaceuticals
ZNTL
$202M
| – | – |
-38,342
| Closed | -$1.08M | – |
|
87
DELISTED
R1 RCM Inc. Common Stock
RCM
| – | – |
-590,819
| Closed | -$12.4M | – |
|
88
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-3,300
| Closed | -$631K | – |
|
89
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-502,587
| Closed | -$5.21M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Eversept Partners held 89 positions worth $1.15B, down 18% from $1.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Eversept Partners withdrew a net $97.3M in Q3 2022, closing 19 positions and reducing 25 holdings. Its most notable exit was AstraZeneca, an estimated $67.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 70% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Eversept Partners opened a new position in Seres Therapeutics worth $12.4M.
- Eversept Partners's largest Q3 2022 buy was Seres Therapeutics: 96,791 shares worth $12.4M.
- Eversept Partners added most to GSK in Q3 2022, an estimated $63.1M increase.
- Eversept Partners's biggest Q3 2022 reduction was Avantor, cutting an estimated $28M.
- Eversept Partners fully exited AstraZeneca in Q3 2022, selling an estimated $67.4M.
- Eversept Partners's ten largest holdings make up 66% of its $1.15B portfolio in Q3 2022.
- Eversept Partners opened 12 new positions and closed 19 in Q3 2022.
- Eversept Partners's portfolio value fell 18% quarter-over-quarter to $1.15B.
Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.